Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | Ovid Therapeutics Inc. |
|---|---|
| Ticker | OVID |
| CIK | 0001636651 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 356,1 Mio. USD |
| Beta | -0,03 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 7,252,000 | -17,414,000 | 150,934,000 | 130,660,000 | |
| 2025-09-30 | 10-Q | 132,000 | -12,158,000 | 63,848,000 | 44,698,000 | |
| 2025-06-30 | 10-Q | 6,272,000 | -4,684,000 | 77,428,000 | 55,789,000 | |
| 2025-03-31 | 10-Q | 130,000 | -10,235,000 | 81,654,000 | 59,276,000 | |
| 2024-12-31 | 10-K | 566,000 | -26,433,000 | 92,167,000 | 68,226,000 | |
| 2024-09-30 | 10-Q | 173,000 | -14,006,000 | -0.20 | 102,654,000 | 76,290,000 |
| 2024-06-30 | 10-Q | 169,000 | 8,521,000 | 0.12 | 118,093,000 | 88,903,000 |
| 2024-03-31 | 10-Q | 148,000 | -11,694,000 | -0.17 | 131,613,000 | 78,279,000 |
| 2023-12-31 | 10-K | 392,000 | -52,339,000 | -0.74 | 144,027,000 | 87,797,000 |
| 2023-09-30 | 10-Q | 109,000 | -11,253,000 | -0.16 | 125,028,691 | 101,294,000 |
| 2023-06-30 | 10-Q | 75,000 | -12,408,000 | -0.18 | 136,229,764 | 110,701,000 |
| 2023-03-31 | 10-Q | 66,000 | -13,356,000 | -0.19 | 143,367,004 | 120,948,000 |
| 2022-12-31 | 10-K | 1,502,748 | -54,169,029 | -0.77 | 155,265,814 | 132,273,000 |
| 2022-09-30 | 10-Q | 11,102 | -11,967,771 | -0.17 | 165,031,865 | 142,050,733 |
| 2022-06-30 | 10-Q | 0 | -14,588,414 | -0.21 | 177,329,852 | 152,147,496 |
| 2022-03-31 | 10-Q | 1,445,366 | -16,108,056 | -0.23 | 191,096,074 | 164,996,271 |
| 2021-12-31 | 10-K | 208,382,779 | 122,834,584 | 1.76 | 194,544,757 | 179,746,436 |
| 2021-09-30 | 10-Q | -11,384,248 | -0.17 | 207,086,188 | 197,021,761 | |
| 2021-06-30 | 10-Q | -15,788,427 | -0.23 | 217,999,299 | 206,709,513 | |
| 2021-03-31 | 10-Q | 176,007,307 | 2.53 | 237,456,030 | 221,109,940 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-23 | ALEXANDER MARGARET A. | Director, Officer, President and CEO | Open Market Sale | -11,656 | 1.45 | -16,901.20 | -115,4% | |
| 2026-02-23 | Rona Jeffrey A | Officer, CBFO | Open Market Sale | -8,541 | 1.45 | -12,384.45 | -84,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.